CNMD

CONMED’s third quarter reflected stability in its core business, with year-over-year sales holding flat and revenue meeting Wall Street’s expectations.

CONMED (CNMD) has investors’ attention after third quarter results showed sales of US$335.56 million, roughly flat year on year, while net income increased to US$19.8 million and earnings guidance for 2026 was narrowed.

Moby summary of CONMED Corporation's Q3 2026 earnings call

CONMED (NYSE:CNMD) reported third-quarter 2026 revenue of $335.6 million, with organic constant-currency sales growth of 6.7% as the medical technology company cited broad-based contributions from its general surgery and orthopedic surgery businesses.

International surgical sales surged double digits amid domestic restructuring headwinds.

Conmed (CNMD) delivered earnings and revenue surprises of +4.00% and -0.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Medical tech company CONMED (NYSE:CNMD) met Wall Street’s revenue expectations in Q3 2026, but revenue was flat year on year at $335.6 million. The company’s full-year revenue outlook of $1.36 billion at the midpoint was close to analysts’ consensus estimates.

(CNMD) on Wednesday reported third-quarter profit of $19.The Largo, Florida-based company said it had net income of 66 cents per share.

Medical tech company CONMED (NYSE:CNMD) will be reporting earnings this Wednesday after the bell. Here’s what you need to know.